EXoZymes Announces Mo Hayat Has Transitioned Out Of His Roles As Chairman Of The Board And President Of EXoZymes, To Focus On New MDB Capital Venture; Christopher Marlett To Assume The Role Of Chairman
EXoZymes Announces Mo Hayat Has Transitioned Out Of His Roles As Chairman Of The Board And President Of EXoZymes, To Focus On New MDB Capital Venture; Christopher Marlett To Assume The Role Of Chairman
eXoZymes Inc. (NASDAQ:EXOZ, formerly Invizyne Technologies))) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - and MDB Capital Holdings (NASDAQ:MDBH) - a premier venture platform for breakthrough technology companies - today announced key leadership changes within the eXoZymes board of directors.
eXoZymes Inc.（納斯達克：EXOZ，前身爲Invizyne Technologies）——一家在人工智能工程酶領域的先鋒，能夠將可持續的原料轉化爲基本的化學品、藥品和生物燃料——以及MDB Capital Holdings（納斯達克：MDBH）——一個爲突破性科技公司提供優質創業平台——今天宣佈eXoZymes董事會內的關鍵領導層變動。
Mo Hayat has transitioned out of his roles as Chairman of the Board and President of eXoZymes, to focus on new MDB Capital ventures. Edgardo Rayo will join the board on behalf of MDB Capital, making it a full circle moment, as he was the MDB Capital team member who discovered the team of scientific co-founders at UCLA and recognized the transformative potential of the science that ultimately evolved into eXoZymes.
Mo Hayat已辭去eXoZymes董事會主席和總裁的職務，以專注於新的MDB Capital創業項目。Edgardo Rayo將代表MDB Capital加入董事會，這標誌着一個圓滿的時刻，因爲他曾是MDB Capital團隊的成員，發現了UCLA的科學聯合創始團隊，並認出了最終發展爲eXoZymes的科學的變革潛力。
Christopher Marlett, CEO of MDB Capital and a current board member of eXoZymes, will assume the role of Chairman to ensure the help and support that MDB Capital will continue to provide eXoZymes.
MDB Capital的首席執行官Christopher Marlett，以及eXoZymes的現任董事會成員，將擔任董事會主席，以確保MDB Capital將繼續爲eXoZymes提供幫助和支持。
熱門市場機會
熱門討論
熱門討論
